Chi-Med CEO Christian Hogg: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Chi-Med CEO Christian Hogg sat down recently with PharmAsia News to discuss how traditional Chinese medicine (TCM) serves as both the foundation for Chi-Med's success and as its platform for growth. Chi-Med is focused on researching, developing, manufacturing and selling pharmaceuticals, health supplements and other health care and personal care products derived from TCM and botanical ingredients.
You may also be interested in...
With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner
BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner
With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner
BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner
Hutchison MediPharma and Eli Lilly Sign New Discovery Deal
BEIJING - Shanghai-headquartered Hutchison MediPharma signed a new partnership agreement with Eli Lilly on drug discovery and development, according to MediPharma's chief executive officer